2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Snapshot: Kisspeptin activates the KISS1R receptor, which regulates gonadotropin-releasing hormone (GnRH) secretion and various other targets. Exogenous kisspeptin-10 directly stimulates GnRH release and influences tumor cell behavior. Kisspeptin may also influence sexual and emotional brain processing, metabolic signaling, vascular and renal biology, and in tumor-cell migration and metastatic pathways.
Kisspeptins are biologically active peptides encoded by the KISS1 gene, which produces several biologically active peptides, including kisspeptin-54 and kisspeptin-10 [1]. All active fragments bind to the same G-protein-coupled receptor, KISS1R [2].
Kisspeptin-10 is the smallest active form of kisspeptin, with the amino acid sequence YNWNSFGLRFamide. Exogenously-administered kisspeptin-10 can directly stimulate GnRH, suggesting that it may have potential therapeutic effects in reproductive medicine and sexual health [3, 4].
KISS1 was originally identified as a metastasis suppressor gene, based on early findings that its expression could inhibit the spread of melanoma and breast cancer cells [5]. The gene is expressed in multiple tissues, including the hypothalamus, gonads, pancreas, adrenal gland, liver, and brain, reflecting both central and peripheral physiological roles [6].
Kisspeptin exerts primary endocrine effects through KISS1R-mediated stimulation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus [2]. When it binds to KISS1R, the receptor activates G-protein-coupled intracellular signalling cascades, which increase the activity and firing of GnRH-secreting neurons [1]. GnRH is released into the hypothalamic-pituitary portal circulation and stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].
Research suggests kisspeptin is a key upstream regulator of reproductive hormone activation, particularly around the onset of puberty, and the full extent of its regulatory control remains an active area of research [2, 7].
Beyond its central role in controlling reproductive hormones, kisspeptin is also studied for possible effects on sexual behavior and emotional processing, metabolic function, and in cancer biology.
Kisspeptin is best known for its central role in activating the reproductive hormone axis via stimulation of GnRH neurons, which in turn drives LH and FSH release and supports sexual maturation and fertility [6].
In a small clinical study enrolling 4–5 subjects per group per gender, subjects received subcutaneous bolus or IV infusion of kisspeptin-10. Healthy male participants had elevated LH and FSH in response to low-dose IV bolus at 0.3 and 1.0 nmol/kg. In contrast, female participants had no serum gonadotrophin responses during their follicular phase, even at doses as high as 720 pmol/kg/min. However, during their preovulatory phases, the serum LH and FSH were elevated after IV bolus of kisspeptin at 10 nmol/kg [3].
In a small comparative study enrolling 5 healthy men per group, vehicle, kisspeptin-10, kisspeptin-54, and GnRH were compared at doses of 0.1, 0.3, and 1.0 nmol/kg/h. Subjects received 3 hours of intravenous therapy. Subsequently, their LH and FSH were tested. The study found that GnRH produced about three-fold the LH and FSH elevation relative to kisspeptin-10, and twice that of kisspeptin-54 [8].
Emerging research also indicates that kisspeptin may influence aspects of emotional processing, bonding, and sexual behavior through its actions in the limbic and hypothalamic brain regions involved in motivation and affective regulation [6].
Both the hormonal and emotional effects appear to operate within reproductive and motivational circuits, rather than broad psychological pathways [6].
Kisspeptin signalling has been identified in several peripheral metabolic tissues, including the pancreas and adipose tissue, suggesting roles beyond reproduction. Experimental work in rodents and humans demonstrated that kisspeptin and its receptor are expressed in pancreatic islets and in vivo models, without affecting basal insulin release [6]. These findings support a context-dependent, glucose-linked action instead of a continuous insulin-stimulatory effect.
Consistent with this, animals created without kisspeptin signalling show increased adiposity, higher leptin levels, and impaired glucose tolerance [6]. This raises the possibility that loss of peripheral kisspeptin signalling may contribute to energy imbalances and metabolic dysregulation [6]. Current evidence supports a modulatory, rather than primary, metabolic role with kisspeptin influencing insulin signaling, adiposity, and glucose tolerance under specific physiological conditions, particularly those linked to reproductive or hormonal status [6].
Kisspeptin was first discovered in cancer research, where restoring KISS1 gene expression in highly metastatic melanoma cells strongly reduced the spread of tumors in animal models, without stopping the original tumor from growing [9]. This led to its classification as a metastasis-suppressor gene [9].
Cell-based studies suggest it does not mainly act by killing cancer cells, but by reducing their ability to move, invade, and migrate [9]. Kisspeptin peptides can slow chemotaxis and invasion, influence matrix-remodelling enzymes, and change cell shape and cytoskeleton dynamics in ways that make cells less mobile and more adhesive [9].
Clinical expression across several cancer types, including melanoma, breast, ovarian, bladder, esophageal, and endometrial cancers, consistently shows that lower KISS1 expression is associated with more advanced or metastatic disease, whereas higher expression is more common in earlier-stage tumors [9].
Current evidence primarily indicates that kisspeptin impacts metastatic potential rather than tumor growth itself, acting as a regulator of how readily cancer cells spread through the body [9].
1 Messager, S., Chatzidaki, E. E., Ma, D., Hendrick, A. G., Zahn, D., Dixon, J., et al. (2005) Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc. Natl. Acad. Sci. U. S. A., Proceedings of the National Academy of Sciences 102, 1761–1766
2 Rønnekleiv, O. K. and Kelly, M. J. (2013) Kisspeptin excitation of GnRH neurons. Adv. Exp. Med. Biol., Springer New York 784, 113–131
3 Jayasena, C. N., Nijher, G. M. K., Comninos, A. N., Abbara, A., Januszewki, A., Vaal, M. L., et al. (2011) The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 96, E1963–72
4 Thurston, L., Hunjan, T., Ertl, N., Wall, M. B., Mills, E. G., Suladze, S., et al. (2022) Effects of kisspeptin administration in women with hypoactive sexual desire disorder: A randomized clinical trial: A randomized clinical trial. JAMA Netw. Open, American Medical Association (AMA) 5, e2236131
5 Lee, J. H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., et al. (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst., Oxford University Press (OUP) 88, 1731–1737
6 Bhattacharya, M. and Babwah, A. V. (2015) Kisspeptin: beyond the brain. Endocrinology, The Endocrine Society 156, 1218–1227
7 Skorupskaite, K., George, J. T. and Anderson, R. A. (2014) The kisspeptin-GnRH pathway in human reproductive health and disease. Hum. Reprod. Update 20, 485–500
8 Jayasena, C. N., Abbara, A., Narayanaswamy, S., Comninos, A. N., Ratnasabapathy, R., Bassett, P., et al. (2015) Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum. Reprod., Oxford University Press (OUP) 30, 1934–1941
9 Mead, E. J., Maguire, J. J., Kuc, R. E. and Davenport, A. P. (2007) Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system: Kisspeptins are multifunctional peptides. Br. J. Pharmacol., Wiley 151, 1143–1153
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Kisspeptin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
What Is KPV Peptide? KPV is a short bioactive peptide composed of three amino acids: lysine (K), proline (P), and valine (V) [1]. It is derived from the larger parent molecule α-melanocyte-stimulating hormone (α-MSH), a peptide hormone that modulates inflammation, pigmentation, circadian rhythm, and immune responses [1]. Unlike the full α-MSH sequence, KPV represents the minimal active fragment capable of exerting anti-inflammatory and protective effects in experimental settings. Because of its small size, KPV is more stable and potentially more amenable to topical or localized delivery compared to its larger parent peptide [2]. KPV is a promising subject of investigation in areas where inflammation and tissue degeneration play central roles, including aging-related disorders. KPV Peptide Mechanism of Action KPV is thought to act through interactions with the melanocortin 1 receptor (MC1R), a G-protein-coupled receptor expressed in a variety of tissues, including skin, intestinal epithelial cells, and immune cells [3]. Anti-Inflammatory Activity One of the most consistent findings across KPV research is its anti-inflammatory activity, particularly in epithelial tissues such as the gut and skin. In preclinical studies, KPV downregulates pro-inflammatory cytokines, including: Tumor necrosis factor-α (TNF-α) [4, 5] Interleukin-1β (IL-1β) [6] Interleukin-6 (IL-6) [4] At the same time, KPV enhanced anti-inflammatory mediators, helping to restore immune balance in tissues that were chronically stressed or damaged. Wound Healing Wound healing is a complex process that requires coordinated activity between keratinocytes, fibroblasts, immune cells, and vascular networks [7]. With aging, this regenerative capacity declines, delaying healing and increasing the risk of chronic wounds and scarring. Research on KPV suggests that it may play a role in supporting tissue repair by modulating inflammation and stimulating cellular regeneration [8]. Animal studies indicate that KPV significantly accelerates keratinocyte migration and proliferation, which promote the re-epithelialization of damaged skin and cornea [9]. By dampening the inflammatory cascade, KPV creates a more favorable environment for tissue recovery [1]. In parallel, KPV has been shown to influence fibroblast activity and extracellular matrix remodeling, processes that underpin scar formation, collagen deposition, and the restoration of skin integrity [10]. In mouse models, KPV accelerates full-thickness wound closure and reduces scarring compared to untreated controls [11]. KPV accomplishes this through increased angiogenesis and collagen deposition. The peptide appears to limit oxidative and inflammatory injury and enhance reparative signaling, striking a balance between protecting cells from further damage and promoting regeneration. KPV Peptide Benefits and Side Effects Gut Barrier Protection In the gut, inflammation disrupts epithelial barrier integrity, leading to increased permeability and impaired nutrient absorption [12]. KPV may counteract this by supporting epithelial repair and reducing inflammatory signaling via inhibiting NF-𝛋B and MAPK signaling pathways [4]. In murine models of inflammatory bowel disease, KPV led to significantly earlier recovery and stronger regain of body weight. The peptide preserved epithelial integrity, reduced oxidative injury, and supported mucosal repair [13]. Skin Health and Repair In dermatological research, KPV has demonstrated the ability to: Reduce swelling Accelerate wound closure Promote keratinocyte migration Promote fibroblast activity In animal models of dermatitis and wound healing, KPV has demonstrated the ability to reduce redness, irritation, and swelling [14]. By balancing cytokine activity and oxidative stress, KPV may treat inflammatory skin conditions and restore healthy skin. KPV may also be particularly relevant to skin aging, where low-level chronic inflammation accelerates collagen degradation, barrier dysfunction, and visible changes [15]. These effects are consistent with its origin as a fragment of α-MSH, a peptide historically studied for its skin-protective properties. Safety/Side Effect Profile KPV is generally well tolerated in experimental settings [16]. Unlike full-length α-MSH or other melanocortin peptides, KPV does not significantly influence pigmentation, reducing the risk of unwanted skin-darkening effects. Preclinical studies report no major systemic toxicity or adverse events, and topical or localized administration appears safe. Although extremely rare, applications of proteins or peptides may run the risk of local irritation or allergic reactions [17]. The evidence base remains limited, with most data derived from animal models, in vitro experiments, or small pilot human studies. Long-term safety, optimal dosing, and potential interactions of KPV with other compounds have yet to be fully established.
What is Liraglutide? Liraglutide (Victoza/Saxenda) is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in appetite regulation, glucose balance, and metabolic signaling [1]. As a modified form of native GLP-1, liraglutide is engineered to resist rapid enzymatic breakdown, allowing it to remain active in the bloodstream far longer than the naturally occurring peptide. This extended activity enables more sustained engagement of GLP-1 receptors, which are found throughout the: Gastrointestinal tract Pancreas Brainstem Peripheral tissues GLP-1 plays a central role in coordinating how the body manages satiety cues, blood-glucose excursions, and nutrient utilization. Liraglutide mechanism of action and benefits Weight loss Liraglutide’s influence on weight regulation stems from its ability to activate GLP-1 receptors involved in: Central satiety signaling of the hypothalamus and brainstem Delayed gastric emptying leading to meal satisfaction Nutrient partitioning A systematic review analyzed the efficacy and safety of liraglutide for weight loss in non-diabetic obese or overweight adults, by synthesizing outcomes from 11 RCTs and 1,328 total participants [2]. The average age of participants was 44.5 years, and the population skewed female (~ 79%). Liraglutide administration resulted in: Significantly greater weight loss versus control (–4.59 kg) Significant reduction in waist circumference (–3.22 cm) Significant improvement in BMI (–1.71 kg/m²) No significant reduction in HbA1c (–0.43%, p > 0.05) The pooled evidence shows that Liraglutide is effective in promoting clinically meaningful weight loss in non-diabetic overweight and obese adults. Metabolic and Cardiovascular Liraglutide’s extended engagement of GLP-1 receptors influences several pathways tied to metabolic efficiency and cardiovascular balance. An RCT evaluated whether liraglutide 1.8 mg/day over 26 weeks improves diabetic cardiomyopathy in 49 type 2 diabetes (DM2) patients without known cardiovascular disease [3]. At the end of the intervention, Liraglutide showed: Significant improvements in diastolic function (reduction in left ventricle (LV) filling pressures) Significant improvements in systolic function - 9mL reduction in stroke volume - 3% reduction in ejection fraction Liraglutide reduced early LV diastolic filling and LV filling pressures, effectively unloading the left ventricle in patients with type 2 diabetes without cardiovascular disease. Although small reductions in stroke volume and ejection fraction occurred, they remained within normal limits. Bone and Joint Health Although best known for its effects on appetite and metabolic regulation, liraglutide has also been studied for its influence on pathways relevant to bone and joint health. GLP-1 receptors are present not only in metabolic tissues but also on osteoblasts, osteoclasts, and chondrocytes, suggesting a broader role in skeletal homeostasis. A meta-analysis evaluated 17 animal studies to determine whether liraglutide improves bone pathology in animal models of osteoporosis [4]. Results showed that Liraglutide: Partially improved bone pathology by enhancing density and maximum mechanical load Significantly improved bone turnover markers (p < 0.05) Increased bone formation (Osteocalcin and P1NP levels) Decreased bone resorption (CTX-I levels) Liraglutide seems to improves osteopenia by: Enhancing osteoblast activity via Wnt signaling and p-AMPK/PGC-1α pathway Suppressing osteoclast activity by inhibiting OPG/RANKL/RANK pathway These findings support liraglutide as a potentially valuable therapy for osteoporosis in diabetic patients, although higher-quality human studies are needed. Other Health Benefits Liver Health Liraglutide has also been shown to improve liver markers in mice models of non-alcoholic fatty liver. Significant reductions were noted in triglyceride content, fasting blood glucose, and LDL [5]. Microbiome By extension of Liraglutide’s gastrointestinal effects, there has been evidence of gut microbiome modulation. Liraglutide increases levels of eubacteria like Bacteroidales and Akkermansia while reducing harmful bacteria like Bacteroides and Lachnospiraceae [5]. Neurocognitive GLP-1 receptors are expressed in several brain regions involved in reward, mood regulation, and cognitive processing. Liraglutide’s protection of brain insulin receptors has been associated with reversal of cognitive impairment and memory loss in mice [6]. These emerging lines of research reflect liraglutide’s broader physiologic relevance, positioning it as a valuable tool for understanding how GLP-1 agonists influence interconnected systems across the body.
